MorphoSys secures option to license Vivoryon’s QPCTL inhibitors for cancer
The option obtained by MorphoSys gives it the rights to globally develop and commercialise Vivoryon’s family of QPCTL inhibitors, including the latter’s lead compound PQ912. Currently, PQ912 had